Search - tctmd.com

Displaying 461 - 480 of 506

Sort: Relevancy | Date

News Daily News

Stent Thrombosis Risk Lower with Xience vs. First-Generation DES

Yael L. Maxwell

March 06, 2012

News Industry News

Boston Scientific Announces Launch of PROMUS Element™ Platinum Chromium Stent System in Japan

February 29, 2012

News Daily News

Resolute Integrity: New Zotarolimus-Eluting Stent Gains FDA Approval

February 20, 2012

Gender-specific outcomes after paclitaxel-eluting stent implantation in Japanese patients with coronary artery disease: a sub-analysis of Japan TAXUS Express2 post-marketing...

Presentation TCT 2012

Gender-specific outcomes after paclitaxel-eluting stent implantation in Japanese patients with coronary artery disease: a sub-analysis of Japan TAXUS Express2 post-marketing...

Presenter: Hiroyuki Okura, Jun-ichi Kotani, Ken Kozuma, Masato Nakamura

January 03, 2012

First Report of A Novel Polymer-Free Dual-Drug Eluting Stent in De Novo Coronary Artery Disease: Results of the First in Man BICARE Trial

Presentation TCT 2012

First Report of A Novel Polymer-Free Dual-Drug Eluting Stent in De Novo Coronary Artery Disease: Results of the First in Man BICARE Trial

Presenter: Mengyue Yu, Bo Xu, Yongjian Wu, Hongbing Yan, Jue Chen, Jie Qian, Chaowei Mu, Fenghuan Hu, Weixian Yang, Shubin Qiao, Yuejin Yang, Run-Lin Gao

January 03, 2012

First Report of A Novel Abluminal Groove Filled Biodegradable Polymer Rapamycin-Eluting Stent in De Novo Coronary Artery Disease: Results of the First in Man FIREHAWK Trial

Presentation TCT 2012

First Report of A Novel Abluminal Groove Filled Biodegradable Polymer Rapamycin-Eluting Stent in De Novo Coronary Artery Disease: Results of the First in Man FIREHAWK Trial

Presenter: Bo Xu, Jie Qian, Alexandra J. Lansky, Yuejin Yang, Shubin Qiao, Yongjian Wu, Jue Chen, Fenghuan Hu, Weixian Yang, Gary S. Mintz, Martin B. Leon, Run-Lin Gao

January 03, 2012

Eight Years Clinical Outcomes After Unrestricted Sirolimus-eluting Stent Implantation for Severe Coronary Artery Disease

Presentation TCT 2012

Eight Years Clinical Outcomes After Unrestricted Sirolimus-eluting Stent Implantation for Severe Coronary Artery Disease

Presenter: Alfonso Ielasi, Azeem Latib, Marco Mussardo, Massimo Ferraro, Maria Angela Gullace, Cosmo Godino, Mauro Carlino, Matteo Montorfano, Alaide Chieffo, Antonio Colombo

January 03, 2012

News Daily News

Clopidogrel Prescriptions Not Being Filled Fast Enough, If at All

Yael L. Maxwell

December 14, 2011

News Conference News

COBRA: Postdilation with Cryoplasty Reduces Restenosis in Diabetic SFA Lesions

November 30, 2011

News Conference News

TWENTE: Zotarolimus DES Noninferior to Everolimus DES at 1 Year

November 28, 2011

News Conference News

Paclitaxel-Eluting Bioabsorbable Stent Shows Advantage over Bare-Metal Version

November 20, 2011

News Industry News

REMEDEE Study Meets Primary Endpoint: OrbusNeich’s Combo™ Dual Therapy Stent Is Non-Inferior to DES

November 13, 2011

News Daily News

DES Associated with Less Downstream Lesion Development than BMS

November 04, 2011

News Industry News

Elixir Medical Corporation Announces Successful Completion of First-In-Man Study Enrollment for Fully Bioresorbable Drug Eluting Coronary Scaffold System

November 02, 2011

News Daily News

Early Study Shows Pelvic Stenting for Erectile Dysfunction Safe, Feasible

October 21, 2011

News Industry News

Boston Scientific Begins Clinical Trial Enrollment for OMEGA™ Platinum Chromium Stent System

October 05, 2011

News Daily News

Long-term Outcomes Similar for Biodegradable-Polymer, Permanent-Polymer DES

September 12, 2011

News Daily News

ISAR-CABG Published: DES Preferred for Saphenous Vein Graft Lesions

September 12, 2011

News Daily News

SES Fractures Raise Revascularization Risk, But Not Beyond 1 Year

August 05, 2011

News Daily News

ESSENCE-DIABETES Published: Xience, Cypher Equally Equipped to Treat Diabetics

August 03, 2011

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.